Status:

NOT_YET_RECRUITING

ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd

Lead Sponsor:

Fudan University

Conditions:

Breast Cancer

Eligibility:

All Genders

18-75 years

Phase:

PHASE2

Brief Summary

A single arm, phase 2 Study of ARX788 in HER2-positive metastatic breast cancer patients who were previously treated with T-DXd. The ARX788 will be administered every 3 weeks (Q3W) intravenous (IV) in...

Eligibility Criteria

Inclusion

  • 18 to 75 years old (including upper and lower limits), male or female;
  • Unresectable locally advanced, recurrent or metastatic BC;
  • Tissue samples determined to be HER2 positive (defined as IHC3+ or FISH+);
  • Received T-DXd treatment in the advanced stage;
  • Adequate bone marrow, liver, kidney and coagulation function;
  • Voluntarily sign the informed consent, have good compliance and are willing to comply with the follow-up visit.

Exclusion

  • With meningeal metastases or disseminated brain metastases or active brain metastases;
  • Has interstitial lung disease requiring steroid therapy, a history of drug-induced interstitial lung disease, a history of radiation pneumonitis, or any evidence indicating clinically active interstitial lung disease;
  • Has any eye disease that require medical intervention such as keratitis, corneal diseases or active eye infection;
  • Has cardiac insufficiency;
  • Has received any systemic anti-tumor therapy (with the exception of endocrine therapy, with an interval of at least 7 days) within 28 days (or at least 5 half-lives) before the first use of the investigational product;

Key Trial Info

Start Date :

September 30 2024

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

September 30 2030

Estimated Enrollment :

44 Patients enrolled

Trial Details

Trial ID

NCT06578286

Start Date

September 30 2024

End Date

September 30 2030

Last Update

August 29 2024

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.

ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd | DecenTrialz